Jounce Therapeutics (NASDAQ:JNCE) Shares Up 12%

Share on StockTwits

Jounce Therapeutics Inc (NASDAQ:JNCE)’s stock price was up 12% during trading on Tuesday . The stock traded as high as $7.77 and last traded at $7.45. Approximately 1,020,500 shares changed hands during mid-day trading, an increase of 73% from the average daily volume of 591,307 shares. The stock had previously closed at $6.65.

A number of equities analysts recently issued reports on JNCE shares. JPMorgan Chase & Co. reiterated a “sell” rating on shares of Jounce Therapeutics in a research report on Friday, August 21st. Raymond James reiterated a “buy” rating and set a $12.00 price objective on shares of Jounce Therapeutics in a research report on Wednesday, September 2nd. Zacks Investment Research cut shares of Jounce Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 13th. ValuEngine upgraded shares of Jounce Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, September 1st. Finally, HC Wainwright upped their price objective on shares of Jounce Therapeutics from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, September 2nd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $9.00.

The company has a debt-to-equity ratio of 0.12, a quick ratio of 8.04 and a current ratio of 8.04. The stock has a market capitalization of $226.55 million, a P/E ratio of 12.02 and a beta of 2.11. The stock’s fifty day simple moving average is $5.12 and its two-hundred day simple moving average is $5.20.

Jounce Therapeutics (NASDAQ:JNCE) last posted its earnings results on Friday, August 7th. The company reported ($0.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.10). As a group, analysts expect that Jounce Therapeutics Inc will post -2.99 earnings per share for the current fiscal year.

In other Jounce Therapeutics news, CFO Kimberlee C. Drapkin sold 7,200 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $8.06, for a total transaction of $58,032.00. Following the sale, the chief financial officer now directly owns 61,708 shares of the company’s stock, valued at approximately $497,366.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 11,110 shares of company stock worth $76,378 over the last three months. Insiders own 43.96% of the company’s stock.

Large investors have recently bought and sold shares of the company. Advisor Group Holdings Inc. boosted its stake in shares of Jounce Therapeutics by 46.5% in the 2nd quarter. Advisor Group Holdings Inc. now owns 6,858 shares of the company’s stock valued at $47,000 after purchasing an additional 2,178 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC bought a new stake in shares of Jounce Therapeutics in the 1st quarter valued at $49,000. Captrust Financial Advisors bought a new stake in shares of Jounce Therapeutics in the 2nd quarter valued at $73,000. Navellier & Associates Inc bought a new stake in shares of Jounce Therapeutics in the 2nd quarter valued at $87,000. Finally, Raymond James & Associates bought a new stake in shares of Jounce Therapeutics in the 1st quarter valued at $61,000. 74.08% of the stock is currently owned by institutional investors.

Jounce Therapeutics Company Profile (NASDAQ:JNCE)

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.

Featured Article: S&P 500 Index

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply